NEKTAR THERAPEUTICSNKTREarnings & Financial Report
Nektar Therapeutics is an American biopharmaceutical company. The company was founded in 1990 and is based in San Francisco, California. The company develops new drug candidates by applying its proprietary PEGylation and advanced polymer conjugate technologies to modify chemical structure of substances, which improves drug characteristics like retention and solubility. It is a technology supplier to a number of pharmaceutical companies including Affymax, Amgen, Merck, Pfizer and UCB Pharma, e...
Revenue
$23.5M
Gross Profit
$13.7M
Operating Profit
$-49.8M
Net Profit
$-52.4M
Gross Margin
58.5%
Operating Margin
-211.9%
Net Margin
-222.9%
YoY Growth
14.6%
EPS
$-3.76
NEKTAR THERAPEUTICS Q2 FY2024 Financial Summary
NEKTAR THERAPEUTICS reported revenue of $23.5M (up 14.6% YoY) for Q2 FY2024, with a net profit of $-52.4M (down 2.4% YoY) (-222.9% margin). Cost of goods sold was $9.7M, operating expenses totaled $63.5M.
Key Financial Metrics
| Total Revenue | $23.5M |
|---|---|
| Net Profit | $-52.4M |
| Gross Margin | 58.5% |
| Operating Margin | -211.9% |
| Report Period | Q2 FY2024 |
Revenue Breakdown
NEKTAR THERAPEUTICS Q2 FY2024 revenue of $23.5M breaks down across 2 segments, led by Non Cash Royalty Revenue Related To Sale Of Future Royalties at $16.8M (71.5% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Non Cash Royalty Revenue Related To Sale Of Future Royalties | $16.8M | 71.5% |
| Products | $6.6M | 28.3% |
NEKTAR THERAPEUTICS Revenue by Segment — Quarterly Trend
NEKTAR THERAPEUTICS revenue by segment across the last 4 reported quarters, showing how each business line (such as Non Cash Royalty Revenue Related To Sale Of Future Royalties and Products) has evolved quarter over quarter.
| Segment | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 | Q1 FY2025 |
|---|---|---|---|---|
| Non Cash Royalty Revenue Related To Sale Of Future Royalties | $21.8M | $11.5M | $11.2M | — |
NEKTAR THERAPEUTICS Annual Revenue by Year
NEKTAR THERAPEUTICS annual revenue history includes year-by-year totals (for example, 2025 revenue was $55.2M).
| Year | Annual Revenue |
|---|---|
| 2025 | $55.2M |
| 2024 | $98.4M |
| 2023 | $90.1M |
| 2022 | $92.1M |
NEKTAR THERAPEUTICS Quarterly Revenue & Net Profit History
NEKTAR THERAPEUTICS results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $21.8M | -25.3% | $-36.1M | -165.4% |
| Q3 FY2025 | $11.8M | -51.1% | $-35.5M | -301.3% |
| Q2 FY2025 | $11.2M | -52.4% | $-41.6M | -372.2% |
| Q1 FY2025 | $10.5M | -51.7% | $-50.9M | -486.4% |
| Q4 FY2024 | $29.2M | +22.1% | $7.3M | 24.9% |
| Q3 FY2024 | $24.1M | -0.1% | $-37.1M | -153.6% |
| Q2 FY2024 | $23.5M | +14.6% | $-52.4M | -222.9% |
| Q1 FY2024 | $21.6M | +0.2% | $-36.8M | -170.1% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $21.6M | $23.5M | $24.1M | $29.2M | $10.5M | $11.2M | $11.8M | $21.8M |
| YoY Growth | 0.2% | 14.6% | -0.1% | 22.1% | -51.7% | -52.4% | -51.1% | -25.3% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $396.0M | $343.3M | $308.0M | $303.9M | $256.2M | $207.5M | $301.3M | $280.4M |
| Liabilities | $269.3M | $263.6M | $259.1M | $243.1M | $242.5M | $231.7M | $216.3M | $190.6M |
| Equity | $126.7M | $79.7M | $48.9M | $60.7M | $13.7M | $-24.2M | $85.1M | $89.8M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-47.9M | $-37.7M | $-43.9M | $-46.2M | $-49.1M | $-45.7M | $-48.8M | $-65.0M |